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Abstract 
Objectives: Implication of immune processes such as inflammation and autoimmunity in 
bipolar disorder (BD) has recently gained increasing attention. Tolerogenic molecules, among 
which HLA-G plays a prominent role, mediate the modulation of such processes. The HLA-G 
locus is characterized by a number of polymorphisms in the non-coding regions including a 
functionally relevant 14 base pair (bp) insertion/deletion (Ins/Del) allele affecting the HLA-G 
expression. We postulate that genetically determined functional differences in immune 
modulation may contribute to immune dysregulation observed in BD.  
Methods: to explore this possibility we analysed genomic DNAs from 561 BD patients and 
161 healthy controls for the HLA-G 14bp Ins/Del dimorphism using a polymerase chain 
reaction-based assay. Genetic associations with BD as well as relationship with demographic 
and/or clinical variables were examined using Chi-square testing.  
Results: we found that the HLA-G 14bp Ins/Ins genotype was significantly more prevalent in 
healthy controls than in BD patients (HLA-G 14bp Ins/Ins vs other genotypes: 22% vs 14 %, p 
= 0.016, corrected p (pc) = 0.032). Subsequent analysis, after stratification of patients based on 
their season of birth, revealed that the prevalence of the protective HLA-G 14bp Ins/Ins 
genotype is lower among patients born during the winter season as compared to those born in 
other periods (HLA-G 14bp Ins/Ins vs the other genotypes: 6% vs 17%, p = 0.003, pc = 0.006).  
Conclusion: possible mechanisms between low HLA G expression and resistance to infections 
as well as potential relationships between infections in early life and susceptibility to BD are 
discussed. 
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1. Introduction 
 Bipolar disorder (BD) is a common severe mental illness ranked as the 4
th
 leading cause of 
disability, affecting 1 to 4% of the population worldwide (Collins et al., 2011). Although the 
pathogenic mechanism remains elusive, BD is recognized as a multifactorial disorder 
involving interactions between multiple genetic and environmental factors (Serretti at al., 
2008; Lichtenstein et al., Lancet, 2009). The reported heritability ranges from 60 to 85% 
indicating that genetic factors are important in the etiopathology of the disorder (Farmer, 
Elkin and McGuffin, 2007) while the significance of environmental factors is highlighted by a 
concordance rate of only 40 to 70% among monozygotic twins (Taylor, Faraone and Tusang, 
2002). Moreover, patients with bipolar disorder show excess of winter births (5.8%) possibly 
associated with early-life environmental infective insult (Moore et al., 2001). Further 
accumulating evidence pinpoints towards an immunological substratum encompassing both 
the innate and adaptive immunity in the etiopathology of BD (for review see Goldstein et al., 
2009 and Hamdani et al., 2011). Indeed, the existence of a chronic low-grade inflammation in 
BD patients both during acute episodes and euthymia is evidenced by the elevated plasma 
levels of various proinflammatory factors (reviewed in Goldstein et al., 2009). Although no 
specific gene influencing immune dysregulation in BD has been identified, genetic 
association between a TNF alpha promoter variant and mood disorders including BD that 
range from clinical conditions close to symptoms of depression (“vital exhaustion” syndrome) 
to late life depression and BD has been reported (Blume et al., 2010; Clerici et al., 2009; 
Czerski et al., 2008). Such immune dysfunction is further strengthened by the preferential 
association of BD with organ-specific auto-immunity, in particular thyroiditis (Padmos et al., 
2004; Vonk et al., 2007; Eaton et al., 2010). Potential contribution of infections in the 
pathogenesis of BD is exemplified by the association between Borna and Herpes simplex 
virus infections and the incidence rate of BD incidence rate (Terayama et al., 2003; Dickerson 
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et al., 2004), although recently contested concerning Borna virus (Hornig et al., 2012). In 
addition, genome-wide association studies (GWAS) demonstrated a significant genetic 
association of the major histocompatibility complex (MHC) regions with BD (Purcell et al., 
2009; Figueiredo and Mendes de Oliveira, 2011).  Altogether these findings raise the 
possibility that impaired immune regulation could be central to the pathogenesis of BD, at 
least in a subset of BD patients and common genetic variations in the immune regulatory 
genes of the MHC region may be associated with the genetic susceptibility to and/ or 
resistance against BD. 
 Among the pivotal modulators of immune function, the human leukocyte antigen-G (HLA-
G) molecules are of particular interest because of their various immunosuppressive/immune 
tolerogenic properties (Rouas-Freiss et al., 1997; Wiendl et al., 2002; Bainbridge et al., 2000). 
Belonging to the non-classical HLA-class Ib family and encoded by a locus mapped telomeric 
to HLA-A gene, the HLA-G molecules are structurally similar to their HLA classical 
counterparts, yet are distinct by their limited tissue distribution in physiological conditions, 
diversity of their protein isoforms [membrane-bound and soluble isoforms (sHLA-G)] and a 
unique pattern of polymorphisms in the non-coding regions especially within the promoter 
and the 3’-untranslated regions (3’UTR) (Paul et al., 2000, Larsen and Hviid, 2009). As 
identified to date, HLA-G gene presents a limited number of exonic polymorphisms with 46 
alleles accounting for 15 protein variants (IMGT/HLA sequence database). Each of these 
alleles bears either a 14-base pair (bp) insertion (Ins) or deletion (Del) polymorphism in the 
3’UTR that influences the HLA-G expression. Indeed, the 14bp Ins allele was demonstrated 
to be associated with low levels of both HLA-G mRNA and circulating sHLA-G isoforms 
(Chen et al., 2008; Rizzo et al., 2008) and hence we denominated it as “low expressor” allele 
(Boukouaci et al., 2011 in press). Reduced expression of HLA-G has been predicted to 
compromise the efficacy of the process of immune tolerance.  
 6 
 Disease association studies implicating the HLA-G locus included a variety of clinical 
entities viz gestational complications, auto-immunity, infections, cancers and solid organ 
transplantation (Larsen and Hviid, 2009). But, to our knowledge, its potential implication in 
psychiatric disorders has not been explored so far. Given the immune dysfunctional 
phenotypes of BD, we investigated, in a case/control study, if the functionally relevant 14 bp 
dimorphism of the HLA-G gene is associated with BD.  
 
2. Materials and Methods: 
2.1. Subjects 
 Five hundred and sixty-one BD patients meeting DSM-IV criteria (A.P.A. 1994) for BD 
(type I or II), consecutively admitted to three French university-affiliated psychiatry 
departments (Paris-Créteil, Bordeaux and Nancy), were interviewed by trained psychiatrists, 
using the French version of the Diagnostic Interview for Genetic Studies (DIGS version 3.0) 
(Nurnberger et al., 1994). All patients were euthymic at inclusion (i.e. having a Montgomery-
Asberg Depression Rating Scale (Montgomery and Asberg, 1979) score and a Mania Rating 
Scale (Bech et al., 1978) score no more than five. A set of demographic and/or clinical 
variables (Table 1) was taken into account and recorded while diagnosing the patients. One 
hundred and sixty-one ethnically matched healthy controls were recruited from blood donors 
at the Pitié-Salpêtrière and Henri Mondor Hospitals (France) and controls interviewed with 
the DIGS for personal history of psychiatric disorders and about family history using the 
National Institute for Mental Health Family Interview for Genetic Studies (Maxwell 1992). 
Only those, with neither personal nor family history (first degree) of psychiatric disorders, 
affective disorders or suicidal behavior were included. All patients and controls were of 
French descent, with at least three grandparents from mainland France. Written informed 
consent was obtained from all participating subjects and the institutional ethical committee 
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approved the research protocol.  
 
2.2. HLA-G genotyping 
  Genomic DNA was extracted from EDTA-treated peripheral blood samples using the 
standard salting out procedure (John et al., 1991). The 14-bp Ins/Del polymorphism 
(rs66554220) in the exon 8 encoding the HLA-G 3’ UTR was genotyped as previously 
described (Tripathi et al., 2004). Briefly, after polymerase chain reaction (PCR), amplified 
products were size-discriminated by agarose gel electrophoresis with appropriate controls of 
known HLA-G genotypes that had previously been characterized by nucleotide sequencing. 
Alleles having the 14 bp sequence in exon 8 was termed HLA-G 14pb Ins whereas those 
without, HLA-G 14pb Del.  
 
2.3. Statistical analysis 
 Comparisons of genotype and allele frequencies between patients and controls were 
performed using the Chi-square testing with Yate’s correction or Fisher exact test whenever 
appropriate. p values (two tailed) were corrected (pc) using the Bonferroni method and 
findings considered statistically significant for pc equal or less than 0.05. Odds Ratio (OR) 
and 95% confidence interval (95% CI) were calculated to assess the relative risk conferred by 
a specific allele or genotype. The following demographic/clinical items i.e. age, gender, 
seasonality of birth, presence of thyroiditis, family history, suicidal behavior, violent suicide 
and polarity of the first episode were included in the analysis. Deviation from Hardy-
Weinberg equilibrium was analyzed using 
2  
testing. 
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3. Results 
 Phenotype characteristics of patient and control groups are summarized in Table 1. For the 
studied polymorphism, the observed genotype distribution satisfied the expected Hardy 
Weinberg proportions for both patient and control samples and the overall frequencies were 
comparable to those previously published in public database (HLA-G 14bp Ins/Ins: 21%, 
HLA-G 14bp Ins/Del: 48% and HLA-G 14bp Del/Del: 31% and HLA-G 14bp Ins/Ins: 22%, 
HLA-G 14bp Ins/Del: 45% and HLA-G 14bp Del/Del: 32% for patients and controls 
respectively) ( http://www.ncbi.nlm.nih.gov/).   
 We found that the HLA-G 14bp Ins allele was less represented in BD patients than in 
controls although failed to reach statistical significance (39% vs 45% in patients and controls 
respectively, p = 0.07; OR= 0.79, CI95%: 0.61-1.03) (Table 1). Nevertheless, analysis of the 
HLA-G 14bp genotype distribution revealed that the homozygous state of 14bp Ins allele was 
significantly more prevalent in healthy controls than in BD patients (HLA-G 14bp Ins/Ins vs 
other genotypes: 22% vs 14 %, p = 0.016, pc = 0.032; OR = 1.71, 95% CI = 1.07 - 2.70) (Fig. 
1a and 1b). Analysis of HLA-G genotype distribution after stratification of patients based on 
their season of birth revealed that the prevalence of the HLA-G 14bp Ins/Ins genotype is less 
prevalent among patients born during the winter season than those born in other periods (HLA-
G 14bp Ins/Ins vs other genotypes: 6% vs 17%, p = 0.003, pc = 0.006; OR = 3.16, 95% CI = 
1.39 - 8.41) (Fig. 2). Concerning the other demographic/clinical variables, no significant 
association with HLA-G alleles/ genotypes was noted. 
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4. Discussion 
 The underlying mechanisms in BD pathogenesis remain elusive albeit biological processes 
such as immune activation and immune suppression seems to parallel BD development and 
evolution (Figueireido and Mendes de Oliveira, 2011; Hamdani et al., 2012; Drexhage et al., 
2011, Blume et al., 2010). Indeed manic and depressive episodes have been associated with 
both the Th1-mediated cellular
 
and the Th2-mediated humoral pathways with the production 
of distinct pro-inflammatory cytokine profiles. In this context, HLA-G molecules, proven to 
be pivotal in immune tolerance through the induction of tolerogenic antigen presenting cells, 
Th2-type cytokines and regulatory T cells and through the inhibition of T cell proliferation, 
cytotoxic T lymphocyte-mediated lysis, NK cell proliferation and NK-mediated lysis 
(reviewed in Donadi et al., 2010) is of particular interest in the studies of immune dysfunction 
in BD.  
 To explore the immuno-genetic susceptibility factors in BD, we studied a functionally 
relevant HLA-G gene polymorphism, namely the HLA-G 14bp Ins/Del variation. We found 
that the presence of the HLA-G 14bp Ins/Ins genotype, (and not the Ins allele), protects 
against the risk of developing BD.  This finding suggests that the protection conferred by the 
HLA-G 14bp Ins allele is dose dependant (recessive). 
 The 14-bp insertion allele, albeit generate more stable HLA-G mRNAs species (O'Brien et 
al., 2001, Rousseau et al., 2003, Hviid et al., 2003), had consistently been associated with low 
expression of HLA-G mRNA and low levels of serum sHLA-G (Chen et al., 2008, Rizzo et 
al., 2008). Such paradox in terms of stability and output is explained by the role of micro 
RNAs which by interacting with the HLA-G 3’mRNA region regulate the HLA-G phenotype 
expression (Veit and Chies, 2009, Castelli et al., 2010). Indeed, two polymorphic positions 
(rs1063320 and rs9380142) have been identified, the former as a binding site for micro RNAs 
with a role to down regulate HLA-G expression (Tan Z et al., 2007) and the latter associated 
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with diminished stability of HLA-G mRNA species (Yie et al., 2008). Interestingly, these two 
variant alleles, affecting overall the HLA G protein expression, are found to be in strong 
linkage disequilibrium with the HLA-G 14bp Ins allele in various population groups (Castelli 
et al., 2010; Tan et al., 2007; Larsen et al., 2010).  
 Our data on the protective effect of the Ins/Ins genotype against BD risk fit perfectly 
within the concept that a downregulated expression of HLA-G molecules could moderate 
immunosuppressive/tolerogenic function with consequent improved protection against 
infectious challenges. Indeed low (associated with 14bp Ins allele) or absent (associated with 
HLA-G*0105N allele) HLA-G expression is protective against viral infections such as 
HTLV-1, human cytomegalovirus or hepatitis C and HIV (reviewed in Donadi et al., 2011). 
On the opposite, upregulation of the HLA-G expression has been shown to promote viral 
escape (Onno et al., 2000, Lozano et al., 2002).  In fact, prenatal exposure to viruses with 
affinity for the Central Nervous System viz polio, rubella, herpes simplex type 2, 
cytomegalovirus or parasite such as T Gondii have previously been proposed as risk factors 
for psychosis (Dickerson et al., 2006, Niebuhr et al., 2008). Although the precise mechanistic 
relationship between BD and infectious events is less clear, the herpes virus type 1 had been 
associated with cognitive impairment (Dickerson et al., 2004), the Epstein - Barr virus (EBV) 
potentially with bipolar depression and the Borna Disease Virus inconsistently with mood 
disorders and BD (Ferszt et al., 1999, Terayama et al., 2003, Hornig et al., 2012) . Altogether, 
the hypothesis is that certain viral infections early in life initiate a cascade of biological 
events, irreversibly establishing a potential for dysregulated immune processes later in life 
and in particular in those genetically susceptible to BD. Two recent studies are in line with 
this hypothesis. In one study, the authors demonstrated that the genetic diversity of the 
cytotoxic T lymphocyte antigen 4 (CTLA4), a central molecule in the control of T-cell 
tolerance, confers risk both to recurrent schizophrenia, major depressive disorders and BD 
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(Liu and al., 2011). In the other study, the authors showed that the percentages of anti-
inflammatory CD4(+) CD25(high) FoxP3+ regulatory T (Treg) cells, which are known to be 
induced by HLA-G (Yan., 2011), were higher in BD patients below 40 years of age as 
compared to healthy controls (Drexhage et al., 2011).  
 Although contested, excess number of Winter/Spring births had been noted among BD 
patients (Torrey et al., 1997; Tsuchiya et al., 2003). We found that the protective effect 
conferred by the low expressor HLA-G Ins/Ins genotype is observed mainly in patients born 
during the winter season, a seasonal window particularly rich in environmental infectious 
challenges (Moore et al., 2001).  Based on this genetic association data we postulate that 
during this seasonal window, individuals bearing the low expressor HLA-G Ins/Ins genotype 
might benefit a better antiviral protection by their capacity to mount more efficient anti-
infectious responses than those with other genotype combinations.  
 This observation could be also related to recent studies highlighting the role of human 
endogenous retrovirus-W (HERV-W) in the development of major psychosis including BD 
(Yolken et al., 2000, Frank et al. 2005, Weis et al., 2007). Representing a part of the human 
genome, the HERV-W elements vary across individuals in terms of copy number and 
chromosomal location (Griffiths et al., 2001) and can be triggered to express their antigens by 
a variety of environmental agents such as Influenza virus with potential seasonal infectious 
“risk” for BD during pregnancy. These elements may also be triggered later in life by Herpes 
viridae primary infections in young adulthood, or EBV or Herpes Simplex viruses (Nellaker 
et al., 2006, Perron et al., 1993). Such reactivation may correspond to the secondary boosting 
of HERV-W pathogenicity towards clinical disease after a long-term sub-clinical phase. This 
could explain why the various above-mentioned infectious agents behave as risk factors for 
BD. 
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 Overall, HLA-G polymorphism behaves as a biomarker for BD and further sub-
stratification of patients based on HLA G genotype and /or seasonality of birth may facilitate 
in identifying other biologic/genetic correlates of the biologically heterogeneous but currently 
clinically labeled as BD. To substantiate this, large trans-population studies are warranted. 
Such studies could help to recognize BD subtypes based on their biological/genetic profiles 
that can have significant impact on the patient subtype-based therapeutic approaches. 
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Figure legends:  
Figure 1a and 1b 
The homozygous state of 14bp Ins allele is significantly more prevalent in healthy controls 
than in bipolar disorder (BD) patients. 
Figure 2 
The HLA-G 14bp Ins/Ins genotype is less prevalent among patients born during the winter 
season than those born in other periods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
